Autoimmune encephalopathy evaluation: Why be comprehensive?

Virtual Lecture

Expires: September 1, 2023


Understanding the rapidly evolving field of autoimmune neurology helps physicians quickly and accurately diagnose this treatable patient population. A review of the phenotype-specific evaluations and the role of paraneoplastic testing can avoid delays in diagnosis and improve efficiency for the lab. The move away from the traditional paraneoplastic approach to testing is the result of decades of well-published research aimed at improving patient care. Proper utilization of the phenotype-specific test menu improves specificity, offers physicians a definitive diagnosis, and shortens the patient journey.


Length of video: 41 minutes


Sean Pittock, M.D.

Sean Pittock, M.D.

Professor of Neurology

Department of Laboratory Medicine and Pathology

Department of Neurology

Mayo Clinic, Rochester, MN

Learning objectives

Upon completion of this activity, participants should be able to:

  • Discuss recent discoveries that led to the creation of phenotype-specific evaluations
  • Recall the different antibody detection methodologies
  • Describe clinical relevance of neural autoantibodies on patient diagnosis, prognosis, and treatment
  • Discuss shortcomings of traditional paraneoplastic approach to autoantibody testing

Intended audience

This program is appropriate for clinicians, pathologists, medical technologists, nurses, pharmacists, and other allied health staff.


The following types of credit are offered for this event:


Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.® program. This program has been approved for a maximum of .5 P.A.C.E.® contact hour.

To obtain credit

1. Watch the video.

2. Complete the posttest and evaluation that launches immediately following the video.

3. Generate and print your certificate(s).

Level of instruction for this program is intermediate.

Faculty disclosure

Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.


Contact us:

MCL Education (@mmledu)

MCL Education

This post was developed by our Education and Technical Publications Team.